Novel Micro RNA as a Tumor Suppressor

Tech ID:
HSC-0988
Description:

The miRNA miR-185 has been shown to inhibit cell proliferation, anchorage independent growth, cell invasion as well as tumor growth and metastasis in immuno-compromised mice.  In addition to it success being systemically delivered to treat tumor growth and metastasis in mice, miR-185 sensitizes resistant cancer cells to cancer treatment drugs including taxol, and TRAIL (a drug currently in clinical trial that spares normal cells).

 

Background:

Tumor growth and metastasis are partially derived from deregulation of genes that are critical regulators of normal development and differentiation. Micro RNAs (miRNAs) are naturally-occurring short non-coding sequences of RNA, involved in many biological processes, and several are being investigated as potential therapeutics for tumor suppression. MiRNAs represent a new generation of cancer therapeutics that function through subtle regulation of a large number of factors. This is in contrast to current therapies that target individual genes and gene products that are prone to insufficient disruption of oncogenic pathways, drug-induced toxicity and acquired drug resistance.  Since miRNAs are stable, endogenously expressed, regulate large numbers of genes, and can be easily manipulated using synthetic oligoribonucleotides, they represent more attractive targets.  

 

Invention: 

Researchers at the University of Texas Health Science Center at San Antonio identified that the miRNA named miR-185 is a potent tumor suppressor.  Furthermore, they showed that miR-185 mediates its anti-proliferative and tumor suppressor functions in part by suppressing expression of potent oncogenes including Six1, which is known to play a central role in the development of poor outcome, aggressive, metastatic adult human cancers, such as breast cancer, ovarian cancer, hepatocellular carcinoma. In addition, miR-185 sensitizes drug-resistant cancer cells to apoptosis in general and TRAIL-mediated apoptosis in particular.               

 

Benefits:

    • miR-185 inhibits cell proliferation, anchorage independent growth, cell invasion as well as tumor growth and metastasis in immuno-compromised mice
    • miR-185 can be systemically delivered to treat tumor growth and metastasis in mice
    • miR-185 sensitizes resistant cancer cells to cancer treatment drugs including taxol, and TRAIL (a drug currently in clinical trial that spares normal cells)

IP Status:  US application, WO 2011/103345

Patent Information:
Category(s):
Therapeutics
For information contact:
Maryellen McCafferty
Business Development Manager
Office of Technology Commercialization
mccaffertymc@uthscsa.edu
Inventors:
Manjeet Rao
J. Saadi Imam
Keywords: